25th January 2019 – Destiny Pharma issued an announcement, which is summarized as
follows:
Two-year programme will research novel antimicrobial candidates
from the Company’s XF drug platform for use against dermal and ocular
infections
Collaboration with Cardiff University and Tianjin
Medical University will aim to identify safe and efficacious compounds with a
reduced resistance profile
Destiny Pharma today announces it has been awarded funding
of up to ￡1.6 million from a collaboration established under
the UK-China AMR grant fund set up by Innovate UK and the
Department of Health and Social Care with the Chinese Ministry of Science and
Technology. The two-year project will examine the use of the Company’s novel XF
drugs to prevent, control, and eradicate life
threatening bacteria or “superbugs” without generating
resistance. The research work will be carried out by Destiny
Pharma’s team in collaboration with expert groups
at Cardiff University’s School, led by Professor David Williams, and
a team at Tianjin Medical University, China.
Neil Clark, Chief Executive Officer of
Destiny Pharma, commented: ”
These newly awarded funds, under the new UK?China collaboration, will help
further explore our XF drug platform. We are
hopeful this collaboration may help us identify additional clinical candidates
that are safe, effective and with a significantly reduced level of
antimicrobial resistance. Destiny Pharma is planning to complete Phase 2 trials
in its lead XF programme, XF-73, in 2019. Destiny Pharma already has
a China regional collaboration with our investor, China Medical
Systems, and we are delighted to expand our strong connections in this significant
market.”
Destiny Pharma is due
to commence a key Phase 2b study for XF-73, its lead asset, in 2019 for the
prevention of post-surgical staphylococcal infections.
Original website link: